Cetin Yuksel, Aydinlik Seyma, Gungor Aysen, Kan Tugce, Avsar Timucin, Durdagi Serdar
Genetic Engineering and Biotechnology Institute, Marmara Research Center (MRC), The Scientific and Technological Research Council of Turkey (TUBITAK), Gebze, Turkey.
Department of Medical Biology, School of Medicine, Bahcesehir University, Istanbul, Turkey.
Curr Med Chem. 2022;29(38):5925-5948. doi: 10.2174/0929867329666220627121416.
The COVID-19 outbreak caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) continues to have high incidence and mortality rate globally. To meet the increasingly growing demand for new therapeutic drugs and vaccines, researchers are developing different diagnostic techniques focused on screening new drugs in clinical use, developing an antibody targeting a SARS-CoV-2 receptor, or interrupting infection/replication mechanisms of SARS-CoV-2. Although many prestigious research publications are addressing this subject, there is no open access platform where all experimental techniques for COVID-19 research can be seen as a whole. Many researchers have accelerated the development of in silico methods, high-throughput screening techniques, and in vitro assays. This development has played an important role in the emergence of improved, innovative strategies, including different antiviral drug development, new drug discovery protocols, combinations of approved drugs, and setting up new drug classes during the COVID-19 outbreak. Hence, the present review discusses the current literature on these modalities, including virtual in silico methods for instant ligand- and target-driven based techniques, nucleic acid amplification tests, and in vitro models based on sensitive cell cultures, tissue equivalents, organoids, and SARS-CoV-2 neutralization systems (lentiviral pseudotype, viral isolates, etc.). This pack of complementary tests informs researchers about the accurate, most relevant emerging techniques available and in vitro assays allow them to understand their strengths and limitations. This review could be a pioneer reference guide for the development of logical algorithmic approaches for new drugs and vaccine strategies against COVID-19.
由严重急性呼吸综合征冠状病毒2(SARS-CoV-2)引起的新型冠状病毒肺炎疫情在全球范围内持续保持高发病率和死亡率。为满足对新型治疗药物和疫苗日益增长的需求,研究人员正在开发不同的诊断技术,重点是筛选临床使用的新药、开发针对SARS-CoV-2受体的抗体或阻断SARS-CoV-2的感染/复制机制。尽管许多著名的研究出版物都在探讨这个主题,但目前还没有一个开放获取的平台能让人们全面了解所有用于新型冠状病毒肺炎研究的实验技术。许多研究人员加快了计算机模拟方法、高通量筛选技术和体外试验的开发。这一进展在改进和创新策略的出现中发挥了重要作用,这些策略包括不同的抗病毒药物开发、新药发现方案、已批准药物的联合使用以及在新型冠状病毒肺炎疫情期间设立新的药物类别。因此,本综述讨论了关于这些方法的当前文献,包括基于即时配体和靶点驱动技术的虚拟计算机模拟方法、核酸扩增试验,以及基于敏感细胞培养、组织等效物、类器官和SARS-CoV-2中和系统(慢病毒假型、病毒分离株等)的体外模型。这一系列互补的试验让研究人员了解现有准确、最相关的新兴技术,体外试验则使他们能够了解这些技术的优势和局限性。本综述可为开发针对新型冠状病毒肺炎的新药和疫苗策略的逻辑算法方法提供开创性的参考指南。